La vendita allo scoperto per Local Bounti dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Local Bounti. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Local Bounti (NYSE:LOCL) Azioni, Report sulle vendite allo scoperto

Local Bounti

Local Bounti Corp is a controlled environment agriculture company. Its business model is based on building local facilities, operated by local teams, to deliver fresh and quality produce to local communities while maintaining a limited carbon footprint. Using proprietary technology to grow leafy greens and herbs in smart greenhouses with a cultivation process that uses less water and land than conventional agriculture, free from herbicides or pesticides, it delivers products that have a longer shelf life, and are good in taste.

S&amp;T Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STBA#NASDAQ">STBA</a>) reported quarterly earnings of $0.83 per share which beat the analyst consensus estimate of $0.81 by 3.11 percent. This is a 6.74 percent decrease over earnings of $0.89 per share from the same period last year. The company reported quarterly sales of $100.072 million which beat the analyst consensus estimate of $99.177 million by 0.90 percent. This is a 3.27 percent increase over sales of $96.899 million the same period last year.

Earnings

Earnings Beats

News

STBA

S&T Bancorp Q2 EPS $0.83 Beats $0.81 Estimate, Sales $100.072M Beat $99.177M Estimate

HNI Q2 2025 Adj. EPS $1.11 Beats $0.83 Estimate, Sales $667.10M Beat $639.59M Estimate

FirstService (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSV#NASDAQ">FSV</a>) reported quarterly earnings of $1.71 per share which beat the analyst consensus estimate of $1.47 by 16.01 percent. This is a 25.74 percent increase over earnings of $1.36 per share from the same period last year. The company reported quarterly sales of $1.416 billion which beat the analyst consensus estimate of $1.401 billion by 1.05 percent. This is a 9.09 percent increase over sales of $1.298 billion the same period last year.

FirstService Q2 Adj. EPS $1.71 Beats $1.47 Estimate, Sales $1.416B Beat $1.401B Estimate

Berkshire Hills Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHLB#NYSE">BHLB</a>) reported quarterly earnings of $0.69 per share which beat the analyst consensus estimate of $0.59 by 16.36 percent. This is a 25.45 percent increase over earnings of $0.55 per share from the same period last year. The company reported quarterly sales of $91.921 million which missed the analyst consensus estimate of $94.150 million by 2.37 percent. This is a 3.83 percent increase over sales of $88.532 million the same period last year.

Earnings Misses

BHLB

Berkshire Hills Bancorp Q2 Adj. EPS $0.69 Beats $0.59 Estimate, Sales $91.921M Miss $94.150M Estimate

Imax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IMAX#NYSE">IMAX</a>) reported quarterly earnings of $0.26 per share which beat the analyst consensus estimate of $0.21 by 24.4 percent. This is a 44.44 percent increase over earnings of $0.18 per share from the same period last year. The company reported quarterly sales of $91.68 million which missed the analyst consensus estimate of $92.51 million by 0.89 percent. This is a 3.06 percent increase over sales of $88.96 million the same period last year.

IMAX

Imax Q2 Adj. EPS $0.26 Beats $0.21 Estimate, Sales $91.68M Miss $92.51M Estimate

Phinia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHIN#NYSE">PHIN</a>) reported quarterly earnings of $1.27 per share which beat the analyst consensus estimate of $1.00 by 27.51 percent. This is a 44.32 percent increase over earnings of $0.88 per share from the same period last year. The company reported quarterly sales of $890.000 million which beat the analyst consensus estimate of $849.913 million by 4.72 percent. This is a 2.53 percent increase over sales of $868.000 million the same period last year.

PHIN

Phinia Q2 Adj. EPS $1.27 Beats $1.00 Estimate, Sales $890.000M Beat $849.913M Estimate

FTI Consulting (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCN#NYSE">FCN</a>) reported quarterly earnings of $2.13 per share which beat the analyst consensus estimate of $1.95 by 9.23 percent. This is a 8.97 percent decrease over earnings of $2.34 per share from the same period last year. The company reported quarterly sales of $943.70 million which beat the analyst consensus estimate of $912.71 million by 3.40 percent. This is a 0.57 percent decrease over sales of $949.16 million the same period last year.

FTI Consulting Q2 EPS $2.13 Beats $1.95 Estimate, Sales $943.70M Beat $912.71M Estimate

Mizuho analyst Siti Panigrahi initiates coverage on Braze (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) with a Outperform rating and announces Price Target of $40.

Price Target

Initiation

Analyst Ratings

BRZE

Mizuho Initiates Coverage On Braze with Outperform Rating, Announces Price Target of $40

2025 First Half Highlights
CM24 (α-CEACAM1 monoclonal antibody)
<ul>
<li>Our Phase 2 dataset demonstrated strong objective response rates (ORR) in biomarker-enriched subgroups of second line PDAC patients, as outlined below. These results suggest compelling efficacy signals. Importantly, these findings reinforce the potentially significant role of our identified biomarkers in guiding future patient selection and clinical trial design.&nbsp;
<ul>
<li>ORR for the intent-to-treat (ITT) group: 25% versus 7% in control group</li>
<li>ORR in biomarker-enriched subgroups: 37.5% (with serum or tumor CEACAM1 levels) and 31% (with serum CEACAM1 or myeloperoxidase (MPO) levels) versus 0% in control group.</li>
</ul>
</li>
<li>Completed final analysis of our Phase 2 study in second-line PDAC and presented results at AACR 2025:
<ul>
<li>Progression-free survival (PFS): hazard ratio (HR)=0.75 in the ITT group; biomarker-enriched subgroups HR=0.22 and 0.39</li>
<li>Overall survival (OS): HR=0.81 in the ITT group; biomarker-enriched subgroups HR=0.05 and 0.28</li>
</ul>
</li>
</ul>
We believe that these results support the advancement of a future biomarker-driven Phase 2b study, with the potential for improved outcomes.
CAPTN-3 Tri-Specific Antibody Platform
<ul>
<li>Presented comprehensive in vivo and ex vivo data at EACR 2025, highlighting the synergistic activity of the platform's masked CD3, NKG2A, and tumor-associated antigen arms.</li>
<li>Novel capping technology demonstrated potential to enhance safety and potency.</li>
</ul>
Platform was spotlighted by Dr. Amir Horowitz at ASGCT 2025 for its approach to targeting the HLA-E/NKG2A axis to selectively activate NK and CD8+ T cells, potentially addressing treatment resistance. NT219 (IRS1/2 degrader &amp; STAT3 blocker)
<ul>
<li>Initiated a Phase 2 combination study with PD-1 or EGFR inhibitors, in collaboration with the University of Colorado</li>
<li>Biomarker insights (pIGF1R, pSTAT3) from the Phase 1 trial were presented at AACR 2025.</li>
</ul>
Upcoming Catalysts
<ul>
<li>Plan to advance CM24 into a biomarker-driven Phase 2b study in second-line PDAC targeting approximately 165 patients</li>
<li>Targeting investigational new drug (IND) application submission to the U.S. Food and Drug Administration for the first development candidate from our novel CAPTN-3 platform in 2026, with plans to initiate first-in-human trials following IND approval.</li>
<li>Expect to generate interim NT219 Phase 2 data in 2026, alongside new preclinical data for next-generation assets.</li>
</ul>
We maintained disciplined cash management in the first half of 2025, and currently expect our financial runway to extend into mid-2026. Additional funding will be required to support the execution of future clinical studies.

Biotech

Health Care

General

PPBT

Purple Biotech's Chief Executive Officer Gil Efron Issued A Letter To Shareholders Highlighting The Company's Scientific Progress, Operational Execution, And Strategic Milestones During 1H 2025

Telsey Advisory Group analyst Cristina Fernandez maintains Academy Sports (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASO#NASDAQ">ASO</a>) with a Outperform and raises the price target from $58 to $65.

Telsey Advisory Group Maintains Outperform on Academy Sports, Raises Price Target to $65

Alterity Therapeutics ((ASX: ATH, NASDAQ:<a href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced&nbsp;that an innovative neuroimaging measure developed in Alterity's Biomarkers of Progression in Multiple System Atrophy (bioMUSE) Natural History Study was featured in the peer-reviewed journal Annals of Clinical and Translational Neurology.
The publication, entitled "The MSA Atrophy Index (MSA-AI): An Imaging Marker for Diagnosis and Clinical Progression in Multiple System Atrophy," describes how deep learning methods, a form of artificial intelligence, were used to precisely define the neuroanatomy of key regions in the brain and the development of a novel brain atrophy measure for tracking disease progression in MSA patients over one year. The results were then correlated with clinical measures of disease severity over the same timeframe.

Alterity Therapeutics Limited - American Depositary Shares

ATHE

Alterity Therapeutics Says Peer-Reviewed Publication In Annals Of Clinical And Translational Neurology Highlights Use Of MSA Atrophy Index Developed To Diagnose And Track Disease Progression In Multiple System Atrophy

Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) CEO Jensen Huang revealed the company&#8217;s straightforward chip allocation process during Wednesday&#8217;s All In Podcast, dismissing concerns about favoritism among tech titans competing for scarce artificial intelligence processors.
What Happened: When asked how he manages allocation requests from high-profile clients like Tesla Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) Elon Musk, Meta Platforms Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) Mark Zuckerberg and OpenAI&#8216;s Sam Altman, Huang offered a surprisingly simple answer: &#8220;Place a PO. That&#8217;s it.&#8221;
Huang said that the company now discloses its roadmap to partners a year in advance for better planning.
Huang addressed supply concerns by revealing he &#8220;wrote off $5 billion worth of Hoppers,&#8221; adding, &#8220;If anybody would like to have some extras, you got them. Just give me a call.&#8221;
The allocation process has become critical as demand for NVIDIA&#8217;s H100 AI chips intensifies. Current Hopper architecture GPUs maintain strong residual value, retaining 75-80% of their original value after one year and approximately 50% after three years.
Responding to Musk&#8217;s projection of deploying &#8220;50 million H100 equivalents&#8221; within five years, Huang described AI infrastructure as requiring &#8220;factories of AI&#8221; that continuously produce tokens. He estimates the industry is &#8220;a couple hundred billion dollars into a multi-trillion dollar infrastructure buildout per year.&#8221;
See Also:&nbsp;<a href="https://www.benzinga.com/markets/tech/25/07/46594334/trump-wanted-to-break-up-nvidia-before-he-learned-the-facts-he-later-found-out-its-not-easy" target="_blank" rel="noreferrer noopener">Trump Wanted To Break Up Nvidia Before He ‘Learned The Facts' — He Later Found Out It's ‘Not Easy'</a>
Why It Matters: The chip shortage has intensified amid <a href="https://www.benzinga.com/25/03/44519562/nvidia-faces-fresh-china-setback-as-chip-shortages-and-sanctions-disrupt-supply">U.S. sanctions affecting Chinese customers</a>. Chinese server maker H3C recently warned of depleted H20 chip inventory, with supply uncertainties extending beyond April. 
Major Chinese firms, including Alibaba Group Holding Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) and Tencent Holdings Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCEHY#OTC">TCEHY</a>) have increased H20 orders following DeepSeek&#8216;s emergence in the AI market.
Previous reports <a href="https://www.benzinga.com/markets/equities/24/09/40893386/elon-musk-and-oracles-larry-ellison-begged-jensen-huang-for-nvidia-gpus-at-a-dinner-please-take-">indicate the competitive dynamics at play</a>. Oracle Corp.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) Larry Ellison and Musk reportedly &#8220;begged&#8221; Huang for additional GPUs during a dinner at Nobu Palo Alto, with Ellison stating they told the CEO to &#8220;please take our money.&#8221;
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46593519/dow-surges-500-points-amid-trumps-trade-deal-deluge-investor-sentiment-improves-fear-index-moves-to-extreme-greed-zone" target="_blank" rel="noreferrer noopener">Dow Surges 500 Points Amid Trump's Trade Deal Deluge: Investor Sentiment Improves, Fear Index Moves To ‘Extreme Greed' Zone</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image via Shutterstock

Tech

BABA

NVDA

ORCL

TCEHY

TSLA

As Elon Musk, Mark Zuckerberg And Sam Altman Chase Nvidia AI Chips, Jensen Huang Says 'Just Call Me' — Here's How Allocation Really Works

Morgan Stanley analyst Megan Alexander maintains Hasbro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAS#NASDAQ">HAS</a>) with a Overweight and raises the price target from $83 to $85.

Morgan Stanley Maintains Overweight on Hasbro, Raises Price Target to $85

Morgan Stanley analyst James Faucette maintains SS&amp;C Technologies Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSNC#NASDAQ">SSNC</a>) with a Equal-Weight and raises the price target from $75 to $88.

SSNC

Morgan Stanley Maintains Equal-Weight on SS&C Technologies Hldgs, Raises Price Target to $88

Dow Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>) shares plummeted Thursday after the chemical manufacturer posted a larger-than-expected loss in the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/n46595836/dow-reports-second-quarter-2025-results" rel="noreferrer noopener">second quarter</a> and cut its dividend in half. The company cited persistent macroeconomic pressure, margin compression, and global trade disruptions as reasons for the cutback.
The company reported an adjusted loss of 42 cents per share, wider than Wall Street&#8217;s projected 12-cent loss, according to <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">consensus estimates</a>. Revenue fell 7% year over year to $10.104 billion, missing the $10.252 billion estimate.
Dow posted a GAAP net loss of $801 million for the quarter, while operating EBIT swung to a loss of $21 million from $819 million in the same period a year ago.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/07/46276683/dow-cuts-800-jobs-shuts-major-european-facilities-to-boost-profit" rel="noreferrer noopener">Dow Cuts 800 Jobs, Shuts Major European Facilities To Boost Profit</a>
Operating cash flow from continuing operations was negative $470 million, a decline of $1.3 billion from the prior year, driven by lower earnings and seasonal working capital needs.
Sales declined across all operating segments. Packaging &amp; Specialty Plastics revenue fell 9% to $5.03 billion, driven by weaker downstream polymer prices.
Industrial Intermediates &amp; Infrastructure revenue declined 6% to $2.78 billion, weighed down by soft demand in construction and mobility.
Performance Materials &amp; Coatings revenue dropped 5% to $2.13 billion, though operating profit improved slightly from the year-ago quarter due to lower input costs and seasonal strength in silicones.
Overall volume decreased 1% year over year, as gains in the U.S. and Canada were offset by declines across Europe, the Middle East, Africa, and India. Local prices fell 7% from the same period last year and 3% sequentially.
Dividend
Dow&#8217;s board <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/n46595865/dow-declares-quarterly-dividend-of-35-cents-per-share" rel="noreferrer noopener">approved</a> a 50% reduction in its quarterly dividend to 35 cents per share, down from 70 cents. The payout is scheduled for September 12 to shareholders of record as of August 29.
The company said the adjustment reflects a more balanced capital allocation approach and aims to preserve financial flexibility amid industry-wide earnings pressure.
&#8220;This quarter, Team Dow advanced several aggressive actions in response to the lower-for-longer earnings environment that our industry is facing, amplified by recent trade and tariff uncertainties,&#8221; commented Jim Fitterling, Dow chair and CEO.
&#8220;We are delivering near-term cash support and earnings growth levers that we expect will total more than $6 billion by 2026. We are also focused on improving margins and optimizing our global portfolio, as seen in our recent European asset actions.&#8221;
Fitterling added that while Dow&#8217;s strategic actions are helping mitigate industry volatility, a wave of low-cost exports from new market entrants is distorting competitive dynamics globally. He said the situation calls for broader industry coordination and potential regulatory intervention to restore market balance.
Outlook
Fitterling stated that Dow&#8217;s near-term growth projects will become fully operational in the third quarter. These, along with the company&#8217;s longer-term investments, are expected to expand Dow&#8217;s presence in higher-value applications and less trade-sensitive end markets.
Dow expects third-quarter 2025 net sales of approximately $10.2 billion versus <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">the consensus of $10.599 billion</a>.
<ul class="wp-block-list">
<li>Packaging &amp; Specialty Plastics: Sales up 1%–3% quarter-over-quarter (Q/Q) on stronger integrated margins and Poly-7 ramp-up, offset by maintenance.</li>
<li>Industrial Intermediates &amp; Infrastructure: Sales up 1% to down 1% Q/Q, with volume gains and reduced maintenance partly offset by lower spreads.</li>
<li>Performance Materials &amp; Coatings: Sales down 2%–4% Q/Q due to seasonal demand declines and margin pressure in upstream siloxanes.</li>
</ul>
Company-wide, ongoing cost reductions continue, with depreciation forecast at $725 million, net interest at $175 million, and the operational tax rate at –40% to –60%.
Price Action: At last check Thursday, DOW shares were trading lower by 9.29% to $27.55 premarket.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/legal/25/07/46595632/doj-adds-significant-personnel-to-hunt-down-tariff-cheats-as-trumps-august-1-deadline-edges-closer" target="_blank" rel="noreferrer noopener">DOJ Adds &#8216;Significant Personnel&#8217; To Hunt Down Tariff Cheats As Trump&#8217;s August 1 Deadline Edges Close</a></li>
</ul>
Photo via Shutterstock

Guidance

Dividends

Movers

Dow Cuts Dividend In Half As Losses Mount And Tariffs Amplify Industry Pain

Morgan Stanley analyst Benjamin Swinburne maintains T-Mobile US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) with a Overweight and raises the price target from $265 to $285.

TMUS

Morgan Stanley Maintains Overweight on T-Mobile US, Raises Price Target to $285

Barclays analyst Christine Cho maintains Wallbox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WBX#NYSE">WBX</a>) with a Overweight and raises the price target from $2 to $7.

Barclays Maintains Overweight on Wallbox, Raises Price Target to $7

Civista Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIVB#NASDAQ">CIVB</a>) reported quarterly earnings of $0.71 per share which met the analyst consensus estimate. This is a 57.78 percent increase over earnings of $0.45 per share from the same period last year. The company reported quarterly sales of $41.40 million which missed the analyst consensus estimate of $42.88 million by 3.45 percent. This is a 8.12 percent increase over sales of $38.29 million the same period last year.

CIVB

Civista Bancshares Q2 EPS $0.71, Inline, Sales $41.40M Miss $42.88M Estimate

Morgan Stanley analyst Cameron Mansson-Perrone maintains Live Nation Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) with a Overweight and raises the price target from $165 to $185.

Morgan Stanley Maintains Overweight on Live Nation Entertainment, Raises Price Target to $185

WIIM

RPM International shares are trading higher following better-than-expected Q4 EPS and sales.

Press Releases

Local Bounti Announces Second Quarter 2024 Financial Results

Local Bounti to Release Third Quarter 2024 Financial Results on Thursday, November 14, 2024

Local Bounti Announces Third Quarter 2024 Financial Results

Commodities

Contracts

Local Bounti Announces Multi-Year Award with Large Multinational Retailer

Local Bounti to Release Full Year 2024 Financial Results on Monday, March 31, 2025

Local Bounti Announces Full Year 2024 Financial Results

Local Bounti to Release First Quarter 2025 Financial Results on Wednesday, May 14, 2025

Local Bounti Announces First Quarter 2025 Financial Results

LOCL

Archer-Daniels-Midland Company Common Stock

Archer-Daniels-Midland

AgriFORCE Growing Systems Ltd. - Common Shares

AgriFORCE Growing Systems

Alico

Bunge Global

Cresud S.A.C.I.F. y A. - American Depositary Shares, each representing ten shares of Common Stock

Comments

Local Bounti

Vendite allo scoperto

Local Bounti (NYSE:LOCL) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO